Clark Austin, Tate Brendan, Urban Bretton, Schroeder Ryan, Gennuso Sonja, Ahmadzadeh Shahab, McGregor David, Girma Brook, Shekoohi Sahar, Kaye Alan D
Health Psychol Res. 2023 Jul 1;11:81043. doi: 10.52965/001c.81043. eCollection 2023.
Bupropion had been in use since the late 1980s as an unconventional treatment for depression. Unlike other antidepressants, bupropion has no serotonergic activity and inhibits the reuptake of norepinephrine and dopamine. The drug has been used to treat depression, Attention Deficit Hyperactivity Disorder (ADHD), and smoking cessation. This investigation reviews the pharmacokinetic and pharmacodynamic effects of bupropion and its mechanisms of action and interactions with other drugs. We evaluated the efficacy of major on and off-label uses of bupropion, focusing on the indications, benefits, and adverse effects. Our review demonstrates that bupropion is superior to placebo and non-inferior to SSRIs such as escitalopram in treating major depressive disorder. More research is needed to determine positive patient-centered outcomes such as increases in quality of life. In the case of ADHD, the evidence for efficacy is mixed with poorly conducted randomized clinical trials, small sample sizes, and a lack of long-term assessments. The same is true in the case of bipolar disorder in which there is still limited and controversial data available on bupropion's safety and efficacy. In the case of smoking cessation, bupropion is found to be an effective anti-smoking drug with synergistic benefits when used as a combination therapy. We conclude that bupropion has the potential to provide benefit for a subset of patients who do not tolerate other typical antidepressants or anti-smoking therapies or for those whose treatment goals align with bupropion's unique side effect profile, such as smokers who wish to quit and lose weight. Additional research is needed to determine the drug's full clinical potential, particularly in the areas of adolescent depression and combination therapy with varenicline or dextromethorphan. Clinicians should use this review to understand the varied uses of the drug and identify the situations and patient populations in which bupropion can lend its greatest benefit.
安非他酮自20世纪80年代末以来一直被用作治疗抑郁症的非传统药物。与其他抗抑郁药不同,安非他酮没有血清素能活性,可抑制去甲肾上腺素和多巴胺的再摄取。该药物已被用于治疗抑郁症、注意力缺陷多动障碍(ADHD)和戒烟。本研究综述了安非他酮的药代动力学和药效学作用及其作用机制以及与其他药物的相互作用。我们评估了安非他酮主要适应证和非适应证使用的疗效,重点关注适应证、益处和不良反应。我们的综述表明,在治疗重度抑郁症方面,安非他酮优于安慰剂且不劣于艾司西酞普兰等选择性5-羟色胺再摄取抑制剂(SSRI)。需要更多研究来确定以患者为中心的积极结果,如生活质量的提高。在ADHD的情况下,疗效证据参差不齐,随机临床试验开展不佳、样本量小且缺乏长期评估。双相情感障碍的情况也是如此,关于安非他酮的安全性和疗效的数据仍然有限且存在争议。在戒烟方面,安非他酮被发现是一种有效的戒烟药物,作为联合治疗使用时具有协同益处。我们得出结论,安非他酮有可能为一部分不耐受其他典型抗抑郁药或戒烟疗法的患者,或那些治疗目标与安非他酮独特副作用特征相符的患者(如希望戒烟并减肥的吸烟者)带来益处。需要更多研究来确定该药物的全部临床潜力,特别是在青少年抑郁症以及与伐尼克兰或右美沙芬联合治疗的领域。临床医生应利用本综述来了解该药物的多种用途,并确定安非他酮能带来最大益处的情况和患者群体。